Every Form 4 that Electra Therapeutics, Inc. (ETRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ETRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ETRA filings page.
Electra Therapeutics, Inc. director and 10% owner Gordon Carl L reported transactions involving securities held by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. On September 21, 2026, at the closing of the issuer’s initial public offering, OrbiMed Private Investments VII, LP’s Series A preferred shares (2,002,310 shares), Series B preferred shares (1,087,934 shares) and Series C preferred shares (1,703,314 shares), and OrbiMed Genesis Master Fund, L.P.’s Series C preferred shares (758,279 shares), automatically converted one-for-one into Common Stock without further consideration.
The funds also purchased Common Stock in the IPO: 333,333 shares by OrbiMed Private Investments VII, LP and 1,000,000 shares by OrbiMed Genesis Master Fund, L.P., each at $15 per share. No Rule 10b5-1 plan is reported.
Electra Therapeutics, Inc. (ETRA) reports that OrbiMed Private Investments VII, LP converted 2,002,310 Series A, 1,087,934 Series B and 1,703,314 Series C preferred shares into common stock on September 21, 2026; OrbiMed Genesis Master Fund, L.P. converted 758,279 Series C preferred shares that day. Each preferred share automatically converted into one common share when Electra’s initial public offering closed, without further consideration. In the IPO, the funds also purchased 333,333 and 1,000,000 common shares, respectively, at $15 per share. OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, each identified as a director and ten-percent owner, jointly reported the transactions and disclaim beneficial ownership except to the extent of any pecuniary interest. OrbiMed Advisors exercises voting and investment power through a committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu; each disclaims beneficial ownership of the fund-held shares. Carl L. Gordon was designated to serve on Electra’s board.
Electra Therapeutics, Inc. (symbol: ETRA) is the issuer of record for a Form 4 filing submitted to the SEC.
Electra Therapeutics, Inc. (ETRA) reported that director Nancy Stagliano converted all of her Series A Convertible Preferred Stock into Common Stock in connection with the closing of the company’s initial public offering. On September 21, 2026, 255,635 preferred shares automatically converted into 255,635 Common Shares on a 1-for-1 basis without further consideration, leaving her with 255,635 Common Shares held directly and no remaining Preferred Stock.
Electra Therapeutics, Inc. (symbol: ETRA) is the issuer of record for a Form 4 filing submitted to the SEC.
Electra Therapeutics, Inc. (ETRA) reported that President & CEO and director Dong Quehuong (Kathy) converted all of her Series A Convertible Preferred Stock into Common Stock on September 21, 2026 in connection with the company’s initial public offering. The conversion produced 455,484 Common shares, which she now holds directly.
Of these shares, 73,147 are Restricted Shares that vest in 13 equal monthly installments beginning September 16, 2026. The Series A Convertible Preferred Stock converted automatically into Common Stock on a one-for-one basis and had no expiration date.